Visudyne

Phase 3

BAYER (BAYRY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Macular Degeneration

IONSIONIS-FB-LRx

Phase 2

View Full Landscape

Drug Information

Target Indication

Macular Degeneration

Clinical Trial

NCT01482910

Last updated: 12/24/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/27/2000

Visudyne

Visudyne is indicated for the treatment of: adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma